Comparative Pharmacology
Head-to-head clinical analysis: PULMOLITE versus SODIUM IODIDE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PULMOLITE versus SODIUM IODIDE I 123.
PULMOLITE vs SODIUM IODIDE I 123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PULMOLITE is a leukotriene receptor antagonist (LTRA) that selectively and competitively inhibits the cysteinyl leukotriene (CysLT1) receptor in the human airway, thereby reducing bronchoconstriction, mucus secretion, and eosinophilic infiltration.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
Adults: 200 mg intravenously every 12 hours over 30 minutes.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10–14 h) in adults with normal renal function (CrCl >90 mL/min); prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min).
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Primarily renal (80%) as unchanged drug; 15% fecal via biliary excretion; 5% metabolized.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical